PharmaShots Magazine -April 2024 Edition

Like every month PharmaShots was occupied following the trail of biopharma updates across the globe. PharmaShots as an official media partner to Reuters Events Pharma USA 2024 was physically present covering the groundbreaking presentations of biopharma companies.??

Our most-read Top 20 Report was dedicated to Women health Focussing Companies & IPOs by Total Fund Value. In the Top-Performing Drug Edition we covered Invega Trinza. The Know Your Investor Report featured Qiming Venture Partners. To honor Alport Syndrome Awareness Month, we prepared a condensed report on Alport Syndrome for our Disease of the Month Report.?

As promised to our audiences, we published A Complete Account of EMA approvals in 2023. PharmaShots, like every month, published reports on the FDA approvals, EMA approvals, biosimilars, & New drug Designations to keep our audiences up to date on the developments in the biopharma industry.?

About the Theme: Telehealth New Way To Primary Care

In a world driven by innovations and digital trends, Telehealth needs no introduction. Yes, the theme for our April Magazine revolves around Telehealth. Telehealth is not just confined to seeking healthcare services remotely using digital technologies but also caters to managing your health care, making it a more diverse and broad term that includes telemedicine and mHealth among others. Our hand-curated magazine unfolds engaging and informative sections with compelling articles, illustrative infographics, BioTrends, Regulatory Updates, and a few enlightening facts on Telehealth.??

Every month PharmaShots explores a new theme and sheds light on real-world practices, trends, and updates on the chosen theme. Our next month’s theme is Policy Reforms.???

Get a chance to be featured in our Magazine! Share your content pieces, advertisements, interviews, and white papers with us on [email protected]?

Going Beyond the Frontiers with Telehealth?

Increasingly popular with the onset of COVID-19, Telehealth has successfully migrated into the healthcare market and is slowly gaining traction. The evolution of telehealth can significantly be attributed to the development of communication and technologies. Telemedicine is often confused with Telehealth and is sometimes used interchangeably. While telemedicine can simply be defined as the practice of receiving healthcare service from a provider online, telehealth is a more of a broader term that combines availing of several healthcare services online, including telemedicine. Telehealth is a portmanteau that denotes seeking healthcare opportunities of any kind remotely using digital technology. Across the UK and other European countries, the term widely used for Telehealth is eHealth. With this article, let’s navigate the aspects of Telehealth and the opportunities it holds in enhancing quality care and mitigating the barriers to healthcare provisions.????

Growing Market?

Telehealth holds a staggering foothold in the market owing to the dramatic downturns experienced by COVID-19. In 2022, the global telehealth market size was valued at $102.7B and is envisioned to reach $893.7B, registering a landmark CAGR of 24.3 percent between 2023 to 2032.?

Breaking the Barriers to Health?

Transforming the predominant factors like accessibility, high costs, and late diagnosis, telehealth manages to break conventional barriers in healthcare. Telehealth even counters successfully the challenges of complex social factors and acts as an advocate for health equity in the real world. It won’t be an exaggeration if we say that Telehealth is going to play a significant role in achieving Health Equity across geographies.???

Harnessing the Immense Potential of Telehealth?

Several tech companies are collaborating with biopharma companies to cultivate a holistic approach to healthcare by adding inclusivity and addressing social determinants in the healthcare sector. Biopharma companies are now at the forefront of reinventing healthcare provisions by aiding new-age innovations to achieve well-rounded growth in health globally. The future of telehealth seems promising owing to the increasing dependence on technology in the healthcare sector. Moreover, healthcare professionals are leveraging Telehealth to optimize and enhance the existing healthcare practices for a better tomorrow.

Insights & Infographics

Regulatory Updates

1. Policy Changes to Shape the Future of Telehealth Across America??

• In 2024, Congress’ legislative agenda included bills that aim to permanently extend facilities provided to patients and clinicians during the COVID-19 pandemic???
• The assembly addressed concerns ranging from Medicare reimbursement, telemedicine providers, telehealth access for underinsured Americans, and online controlled substance prescribing to policies related to the telehealth industry??
• Over the years, the flexibility of telehealth has allowed physicians to receive compensation regardless of the mode of consulting chosen (physical or virtual) which in turn has increased the number of visits under Medicare from 860,000 in 2019 to ~53M within a year???
• Moreover, telehealth has also allowed underinsured Americans to gain access to online healthcare??
• Telehealth industry leaders also expect the assembly to bring a permanent policy over the online prescribing of controlled substances?

Source

2. Florida Government Passes Bill to Allow Telehealth Recertification for Medical Marijuana??

• In May 2023, the Florida Legislature passed the HB 387 bill to expand the use of telehealth as a source of medical marijuana recertification. The new law became effective as of Jul 01, 2023, following the signing of the Florida Governor??
• The new law does not change the existing requirement for a physician to conduct an in-person, physical examination of the patient before issuing an initial certification for the medical use of marijuana???
• Earlier, telehealth was temporarily being used for medical marijuana recertification during the COVID-19 pandemic across Florida

Source

3. The Establishment of a New Advisory Committee for Digital Health Technologies by the US FDA??

• On Oct 2023, the US FDA reported the establishment of a new Digital Health Advisory Committee to address the complex, scientific, and technical issues related to digital technologies incl. artificial intelligence, machine learning, augmented reality, virtual reality, digital therapies, wearables, remote patient monitoring, and software?
• The newly formed committee will advise the US FDA on DHTs related issues to help improve the understanding of the benefits, risks, and clinical outcomes related to DHTs?
• The US FDA will also seek the committee’s advice on the innovation of effective digital health technologies

Source

Did You Know?

Bio-Trends

Our Bio-Trends section is thoughtfully designed to keep our readers acquainted with the trailblazing practices in the life science industry.

With this month’s theme on “Telehealth: the new way to primary care”

Objective:

To assess and draw trends to understand the key telehealth companies operating globally from year 2023.

Methodology:

• Tool used: Google, Press Release
• Keywords used: After going through multiple reports, we have decided to go ahead with the names of top telehealth companies globally. Names as follow: Teladoc Health, Amwell, Talkspace, MDLiveCare, Doctor on Demand. There were multiple other companies also but these were the top trending companies in 2023 related to telehealth and teleconsultation. There were more companies such as LiveHealth Online, Hytro (now Klara Health), 98point6, 20/20NOW (acquired by EyeCare Partners in 2023)
• Time Period: Jan 1, 2023 – Dec 31, 2023
• Filter Criteria: Worldwide across Web & News Search
• Note: This is not promotion material

Key Insights

Insights from Web search

• Peak Interest: The highest average search interest was recorded for Teladoc Health, peaking at 100 on December 31, 2023.
• Steady Performers: MDLiveCare and Talkspace showed consistent interest levels, with MDLiveCare often scoring around 8 and Talkspace around 4.
• Lowest Interest: Doctor on Demand, Inc. consistently had the lowest search interest, with scores generally at 0 or rising to 4 at most.
• Trending Pattern: There is a noticeable trend where interest in Teladoc Health significantly increases towards the end of the year, suggesting a seasonal pattern or a specific event driving the searches.

Insights from Web search

• Spike in Interest: There were notable spikes in search interest for Teladoc Health on April 2, 2023, and June 18, 2023, reaching 100 on the index.
• Amwell’s Peak: Amwell experienced a significant peak on May 7, 2023, with an index value of 71.
• Overall Trends: The data indicates that Teladoc Health had the highest search interest among the listed companies during the observed period.
• Fluctuations: The interest levels fluctuated over time, with periods of no data points, suggesting intermittent public attention or varying events impacting search behavior

Discussion:

There were several limitations and shortcomings to the analysis:

• The data reflect overall trends in the space, and some keywords were not included for various reasons.
• Regional variations in search terms and internet access may skew the data.
• Specific keywords used in searches may not always accurately represent the intended topic.
• The trend analysis was limited to a specific set of keywords and did not cover all therapy areas.

Sponsors & Advertisements

Contact us at [email protected] to advertise here in PharmaShots Magazine.

Top 20 Women Health Focusing Companies

• While the World celebrated International Women’s Day, PharmaShots was busy preparing an exciting report on the Top 20 Women Health Focusing Companies Based on Market Cap?
• Women's Health Market size was valued at $38.10B in 2023 and is expected to register $58.10B by 2030 with a CAGR of 4.9 percent. AbbVie managed to secure the first position with a market cap of $319.84B following the acquisition of Allergan, followed by Abbott Laboratories with $207.08B and Fuzi Pharma Co. Ltd with $281.9M respectively?
• To get a curated report of your liking, reach out to us at [email protected] with the subject line Bespoke?

Click here to read the full article

Top 20 IPO of 2023 in Healthcare by Total Fund Value

• Clinical-stage biopharma companies are in constant need of funding and the best way to pull in money in such dire situations is by going public. 2023 had been a great year for Wall Streets across the globe with continuous announcements of IPOs?
• Kenvue by bagging $4.37B upon completion of its IPO ranked first in our list followed by ACELYRIN and WuXi XDC Cayman, nabbing $621M and $520M respectively?
• Using DealForma's invaluable insights, PharmaShots brings a concise on the Top 20 IPOs in Healthcare by Total Fund Value?

Click here to read the full article

Insights+ Key Biosimilars Events of February 2024

• Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency???
• Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients???
• During February, Sandoz received Health Canada’s approval for Jubbonti while Rani Therapeutics reported the results for its RT-111 Capsules. Our team at PharmaShots has summarized 12 key events of the biosimilar space of February 2024?

Click here to read the full article

Disease of the Month: Alport Syndrome

• To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research??

• In the next installment to our disease report, this month we have covered a detailed analysis of Alport Syndrome, which is a rare genetic disorder characterized by kidney disease, compromised vision, and hearing loss?
• March is observed as Alport Syndrome Awareness Month, an initiative to raise awareness of the genetic disorder?

Click here to read the full article

New Drug Designations – February 2024

• PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, and EC. This month’s report includes designations allotted to 13 small molecules, 20 biologics, and 2 devices??
• SN Bioscience’s SNB-101 received ODD from the US FDA for the treatment of pancreatic cancer based on preclinical results. It has previously received the US FDA’s ODD for treating SCLC in Jul 2023??
• PharmaShots has compiled a list of a total of 33 drugs and 2 devices awarded with designations by multiple regulatory bodies in Feb 2024

Click here to read the full article?

The US FDA New Drug Approvals in February 2024

• PharmaShots has compiled a list of US FDA-approved drugs in the month?of February 2024??
• The US FDA approved a total?of 7 drugs including 6 new molecular entities?and 1 biologic leading to the treatments for patients and advances in the healthcare industry? ??
• The major highlighted drug was Takeda’s Eohilia (budesonide oral suspension) for treating?eosinophilic esophagitis (EoE)?

Click here to read the full article

EMA Marketing Authorization of New Drugs in February 2024

• The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry?
• In February 2024, the major highlighted drugs were Reblozyl?to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis?
• PharmaShots has compiled a list of a total of 9 new drugs approved by the EMA in February 2024?

Click here to read the full article

2023 EMA Marketing Authorization of New Drugs

• In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology??
• PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology??
• For the complete report with analysis, reach out to us at?[email protected]?

Click here to read the full article

Top Performing Drug – Invega Trinza (March Edition)

• In continuation to our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Invega Trinza and prepared an engaging analysis for our readers????
• Invega Trinza (3-Months injection) is an atypical antipsychotic drug used for the treatment of schizophrenia in patients after adequately being treated with Invega Sustenna (once a month)??
• PharmaShots presents a concise take on the key features of Invega Trinza with a detailed analysis of its revenue, clinical trials, alternatives, and approvals. The report is concluded with an engaging SWOT analysis and informative KOL reviews

Click here to read the full article?

Know Your Investor (March Edition): Qiming Venture Partners

• In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and Healthcare?

• In 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11 in the third, and 6 in the fourth quarter respectively. The company’s highest investment in the seed stage was made to Brise Pharmaceuticals worth $140M?
• For a detailed report on all the Qiming’s investments in 2023, reach out to us at [email protected] with the subject line Qiming Venture Partners?

Click here to read the full article?

Reflecting on How the Ripple Effects From COVID-19 Has Impacted the Cost of Living

Click here to read the full article?

Tips for Suboxone Users to Prevent Tooth Decay and Gum Disease

Click here to read the full article?

How Innovations in Technology Can Mitigate Healthcare Disparities

Click here to read the full article?

How to Get Hold of the Best Kratom While Sitting at Home?

Click here to read the full article?

Email us at [email protected] to get a free PDF copy of PharmaShots Magazine edition for Apr 2024. Or you can download from here

Want to advertise in PharmaShots Magazine for FREE? Email us at [email protected]